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Abstract
Background: Scientific publishing is undergoing significant changes due to the growth of online publications, increases in
the number of open access journals, and policies of funders and universities requiring authors to ensure that their
publications become publicly accessible. Most studies of the impact of these changes have focused on the growth of
articles available through open access or the number of open-access journals. Here, we investigated access to publications
at a number of institutes and universities around the world, focusing on publications in HIV vaccine research – an area of
biomedical research with special importance to the developing world.
Methods and Findings: We selected research papers in HIV vaccine research field, creating: 1) a first set of 50 most recently
published papers with keywords ‘‘HIV vaccine’’ and 2) a second set of 200 articles randomly selected from those cited in the
first set. Access to the majority (80%) of the recently published articles required subscription, while cited literature was
much more accessible (67% freely available online). Subscriptions at a number of institutions around the world were
assessed for providing access to subscription-only articles from the two sets. The access levels varied widely, ranging among
institutions from 20% to 90%. Through the WHO-supported HINARI program, institutes in low-income countries had access
comparable to that of institutes in the North. Finally, we examined the response rates for reprint requests sent to
corresponding authors, a method commonly used before internet access became widespread. Contacting corresponding
authors with requests for electronic copies of articles by email resulted in a 55-60% success rate, although in some cases it
took up to 1.5 months to get a response.
Conclusions: While research articles are increasingly available on the internet in open access format, institutional
subscriptions continue to play an important role. However, subscriptions do not provide access to the full range of HIV
vaccine research literature. Access to papers through subscriptions is complemented by a variety of other means, including
emailing corresponding authors, joint affiliations, use of someone else’s login information and posting requests on message
boards. This complex picture makes it difficult to assess the real ability of scientists to access literature, but the observed
differences in access levels between institutions suggest an unlevel playing field, in which some researchers have to spend
more efforts than others to obtain the same information.
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Introduction
Sharing the results of research through peer-reviewed publica-
tion is intrinsic to the scientific process and to progress in science.
It is also widely appreciated that access to scientific findings can
lead to important advances in health care by providing the
evidence upon which to base sound public policy, and by bringing
together researchers from the developed and developing world,
thereby fostering new collaborations and building capacity.
Moreover, it is in everyone’s interests if the public, which provides
a large proportion of the funds required for scientific research
through taxes, and many of whom chose to volunteer for clinical
trials, is actively aware of and engaged in the activities of the
research community. Although the public can’t be expected to
have the same technical expertise as the scientific community, an
engaged public that knows that the scientific community is
accountable and transparent will likely be more supportive of
research and will be more likely to agree to serve as trial volunteers
[1]. For these reasons, various global health organizations and
alliances have called for both increased access and sharing of
research data and primary publications [2–4]. The 2010 Scientific
Strategic Plan of the Global HIV Vaccine Enterprise states that
the field should ‘‘seek consensus on the principle of rapid access to
data and develop a global approach to develop the infrastructure
required to annotate, deposit, and analyze the increasingly large
and complex amounts of laboratory, clinical and population data
generated in the search for an HIV vaccine’’[4].
Recent advances in information technology and computational
techniques have created new opportunities to share both data and
publications rapidly. At the same time, these in silico advances have
been matched by newer technologies capable of generating very
large and complex datasets (e.g. next generation sequencing,
‘omics technologies and other high-throughput approaches).
There is, therefore, both an urgent need and an opportunity for
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and publications. The volume of scientific publications has been
growing at an exponential rate and is stressing the budgets of
university libraries, a situation referred to as the ‘serials crisis’ [5].
At the same time, the globalization of science and increasing
involvement of researchers from the developing world in the
scientific enterprise makes it imperative that scientific information
be available on a level playing field throughout the world. The
revolution in information technology and specifically the devel-
opment of the web has revolutionized scientific publishing itself,
making it possible to disseminate papers anywhere in the world,
easily, inexpensively and rapidly.
Rapid access to data and publications is of particular
importance to the developing world. Infectious diseases such as
HIV, malaria, and tuberculosis disproportionately affect people in
the developing world - out of 33 million people estimated to be
living with HIV in the world, 26 million live in sub-Saharan Africa
and South-East Asia [6]. Over $800 million are invested annually
in HIV vaccine research, making it one of if not the largest single
area of research investment for diseases affecting the developing
world [7]. Yet the overwhelming majority of research funds and
researchers come from North America and Europe. Because the
outcomes of HIV vaccine research are of critical importance for
Africa and Asia, not only for scientists in those regions, but also for
health professionals, regulators, policy makers and affected
communities, it is important to evaluate how research findings
are disseminated. The area of HIV vaccine research, similar to
other biomedical fields, saw recent growth in the popularity of
open-access journals, such as PLoS Pathogens and Retrovirology, but
the exact impact of these changes is not yet clear. For these
reasons, we set out to use the field of HIV vaccine research as a
barometer to measure the degree to which scientists have access to
published research that is of critical importance in this fast-moving
field.
Our approach was as follows: We assessed the literature related
to HIV vaccine research through two sets of papers. The first set,
‘‘recent papers’’, was created by searching for ‘‘HIV vaccine’’ in
the NCBI database on December 6, 2010 and selecting the 50
most recently published articles, checking for relevance and
excluding special-issue publications containing collections of
articles. The second set, ‘‘cited papers’’, was created by randomly
selecting 20 papers from the first set and then randomly selecting
10 citations from each of those papers, resulting in a dataset of 200
papers. We assessed the ability of researchers at a number of
institutions around the world to access both sets of papers online
either by reviewing lists of institutional subscriptions (when




In the recent Study of Open Access Publishing (SOAP)
conducted by the European Commission, 89% of scientists viewed
open access as beneficial and conducive to scientific progress, but
at the same time only 25% were willing to publish in open access
journals [8]. Reviewing our ‘‘recent’’ set of papers, we found that
only 20% were available in open access upon publication (Fig. 1).
Grant policies of many funding organizations, including the
NIH (the largest funder of HIV vaccine research), require that
papers resulting from their financial support become freely
available within 12 months after publication [9]. However, many
subscription-based scientific journals go beyond this requirement
by making papers available sooner (6–9 months after publication).
In addition, some universities require that research publications by
faculty be publicly accessible within a certain period of time.
Perhaps as a result of these policies, papers from the ‘‘cited’’
dataset were significantly more accessible than ‘‘recent’’ papers,
with 67% being available without a subscription (Fig. 1).
Nevertheless, almost one third of publications were not accessible
to investigators who do not have a subscription (five papers, or
2.5%, were too old to be available online). From 134 ‘‘cited’’
papers available without a subscription, 117 were available on the
journal’s website and 12 were available through PubMed Central.
Only a small fraction of the publications (5 out of 200 or 2.5%)
Figure 1. Availability of HIV vaccine research articles online.
Two randomly selected sets of papers were created and checked for
availability online. Most of the recently published papers required
subscription for access, while the ‘‘cited’’ set of papers (randomly
selected from citations within the ‘‘recent’’ set) were more accessible,
presumably due to journals moving articles from subscription-restricted
content into open access. A small proportion of cited articles were not
available online.
doi:10.1371/journal.pone.0027868.g001
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or in institutional databases (so called ‘‘green road’’ to access).
Subscription-based access
Institutes and universities have to make choices when selecting
journal subscriptions. These decisions are presumably based on
the budget of the library and the research interests of the scientists.
As a result, subscription patterns vary widely amongst institutions
and do not necessarily provide access to all subscription-based
literature. We decided to compare the level of access at several
research institutes and universities around the world, focusing on
those that are involved in HIV research.
United States. We first looked at literature access at
Rockefeller University. Rockefeller University has a very active
research program, including several laboratories working on HIV,
and maintains an extensive library. Interestingly, despite an
annual subscription budget of approximately one million dollars,
the university still does not have access to all the articles in our
datasets. In both ‘‘recent’’ and ‘‘cited’’ sets, only 80–85% of papers
requiring subscription were accessible through the Rockefeller
University library website (Fig. 2). This observation is a vivid
illustration of the ‘‘serials crisis’’ affecting even well funded
academic libraries [5].
Sub-Saharan Africa. Sub-Saharan Africa is the region most
affected by HIV. This region of the world also includes countries
with some of the lowest Gross Domestic Product (GDP) per capita.
Thus, institutions in this region would not be expected to afford
journal subscriptions on par with Rockefeller University or other
institutions in North America and Europe. Fortunately, the
WHO-supported Health Internetwork Access to Research
Initiative (HINARI) provides free access to registered institutions
in many countries in the region, including Democratic Republic of
Congo, Gambia, Kenya, Malawi, Nigeria, Tanzania, Uganda,
Zimbabwe and others [10]. For our sets of papers, the level of
access through HINARI matched that of Rockefeller University
for ‘‘cited’’ literature (82%) and was only a little lower for ‘‘recent’’
literature (65%) (Fig. 2).
Republic of South Africa. We chose to look at the access
issue in South Africa for several reasons: First, South Africa has the
unfortunate distinction of having one of the highest rates of
incidence of HIV in the world. Second, South Africa has an
especially strong scientific community by both African and
international standards and South African scientists at public
institutes and universities actively collaborate with investigators in
the North and are involved in a wide array of HIV-related
research projects. Third, South Africa is one of the more
prosperous countries in the region and hence does not qualify
for access through HINARI. As shown in Fig. 2, only 50% of
‘‘recent’’ literature was available through subscriptions at the
National Health Laboratory (NHL) and the access to ‘‘cited’’
literature was even lower (42%). Thus, South African institutions,
such as the NHL, actually have a lower level of access to the
literature than institutions in less-prosperous neighboring
countries.
Brazil and Russia. The economies of Brazil and Russia (in
both absolute numbers and per capita) are similar to each other,
and both countries are facing a growing HIV epidemic. Brazil’s
University of Sao Paolo had the highest level of access among all
institutions we surveyed, surpassing Rockefeller University with
access to 90% of ‘‘recent’’ papers and to 82% of ‘‘cited’’ papers
(Fig. 2). In contrast, Moscow State University, the most prestigious
and best-funded university in Russia, had a mediocre level of
access to ‘‘cited’’ literature (63%), and access to ‘‘recent’’ literature
(35%) was one of the lowest that we observed (Fig. 2). Thus, there
was a significant difference in the level of access to the HIV
vaccine literature in these two countries.
Thailand. We considered two institutions in Thailand, a
country which has been actively engaged in HIV vaccine research.
Through the Thai Ministry of Public Health, over 16,000 Thai
citizens participated as volunteers in RV144, a clinical trial of an
HIV vaccine regimen which was the first trial to show partial,
transient efficacy in the prevention of HIV transmission [11]. We
observed that Mahidol University, the largest university in
Thailand, had excellent access to the ‘‘cited’’ literature (86%),
but only 50% of ‘‘recent’’ papers were available. In contrast,
AFRIMS, a Thai-US collaborative institute of medical research
had the lowest level of access to both ‘‘recent’’ (20%) and ‘‘cited’’
(28%) papers (Fig. 2) among institutions that we surveyed. Many
Figure 2. Subscription-based availability of HIV vaccine research articles at a number of institutes and universities around the
world. The ‘‘recent’’ and ‘‘cited’’ are the two sets of papers described in the legend to Fig. 1. Only papers which were not available through open
access sources, but were available online, were included in this analysis.
doi:10.1371/journal.pone.0027868.g002
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Reed Institute and, perhaps, are able to access papers through
subscriptions at that institute (although we did not evaluate that
possibility in this study).
Requesting reprints
In the past, before the growth of the internet, requesting a
reprint from authors via post mail was a common way to obtain a
copy of a paper. We investigated whether such requests, but now
through email, can compensate for the lack of institutional
subscription. We contacted the corresponding author (if informa-
tion on corresponding author was not available, we assumed that it
was the last author) with a request for a reprint using a sender
email address not affiliated with any institution and with a name
unknown to the authors in order to mirror a common situation in
which the researcher is not familiar with the person requesting the
article. For ‘‘recent’’ papers, we sent out 40 requests and received
24 positive responses (60% success rate) (Fig. 3). For ‘‘cited’’
papers, we intended to send out 65 requests, but could not locate
the email addresses of eight of the corresponding authors. For the
remaining 57, requests were sent out and 31 authors responded by
sending a copy of the paper (54% success rate). Among the 26
emails that were unsuccessful, 8 email addresses were outdated,
one author declined to provide the paper citing copyright issues
with the journal and the rest did not respond. The two thirds of
those who replied to the request did so on the same day or the
next. However, the other third of respondents took on average 11
days to reply (median 3 days, maximum 54 days).
Discussion
In this study, we have presented a data-driven, global
comparison of access to the scientific literature. We chose to focus
our attention on HIV vaccine research - an area of intense
research activity with special relevance for the developing world.
We found that 20% of recent articles in this field were published in
open-access journals. This proportion is a larger fraction than the
10% found in the recent SOAP study [8] or the 7.7% estimated by
Laakso et al. [12], both of which surveyed all scientific publishing.
Therefore, it could be argued that HIV research is more open
than research in other fields. Unfortunately, we do not have data
to compare the HIV vaccine field to other areas of biomedical
research.
Our survey of institutional subscriptions around the world
resulted in widely varying levels of access, with researchers at some
institutions having access to only 20% of subscription-based
publications while researchers in other institutions had access to
90% of these publications. The WHO-sponsored HINARI access
program at institutions in low-income countries, particularly in
Sub-Saharan Africa, has undoubtedly had a very significant
impact on publication access at these institutions, providing
scientists in those countries access on par with that available at
major research institutions in the North. It is important to note
that HINARI is only available to not-for-profit and governmental
institutions. However, it has been argued that for-profit companies
in the private sector are also essential for the growth of scientific
capacity in the developing world and for the development of
products required for controlling diseases that preferentially affect
the developing world [13]. Thus, an expansion of the HINARI
model to local companies involved in biomedical research and
development may be beneficial. Similar to the current country-
level distinction between those who can afford subscriptions and
those who can’t, access through HINARI could be provided to
small start-ups and biotech companies that are operating at a loss
or with small profit margins.
Our results suggest that even well endowed research universities
in the North lack access to all of the HIV vaccine research
literature. Therefore, the research community must use other
strategies besides an institutional subscription if they wish to access
the entire body of literature. Anecdotal responses from researchers
whom we contacted suggest that the research community uses a
variety of approaches to access the scientific literature when they
lack access at their own institutions (Table 1). Researchers
sometimes contact colleagues whose institutions may have
subscriptions to journals that their institution does not provide.
Some use the login and passwords from other institutions - either
officially, by virtue of an adjunct affiliation, or unofficially, by
acquiring login information from colleagues. Some use the option
Figure 3. Outcomes of contacting authors with an email
request for a copy of the paper. The ‘‘recent’’ and ‘‘cited’’ are the
two sets of papers described in the legend to Fig. 1. Emails were
obtained from journal’s website, NCBI, by web searches and in
institution’s directories. ‘‘Positive responses’’ include responses with a
pdf or Word document of the requested paper attached to the email.
‘‘No response’’ includes bounced emails (due to email address no
longer being active), lack of reply and, in one case, refusal to send a
copy due to publisher holding the copyright. ‘‘Email not found’’
includes articles for which the email of the corresponding author could
not be located.
doi:10.1371/journal.pone.0027868.g003
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while others opt for personal subscriptions to compensate for the
lack of institutional subscription. For example, the Ivanovski
Institute of Virology in Moscow does not subscribe to any English-
language journals. When asked about procedures to access the
English language literature, researchers at this and other institutes
in Russia reported that it is common for heads of laboratories to
purchase personal subscriptions to journals that they consider
critical, while the rest of the literature is usually accessed through
contacts with colleagues abroad, often facilitated by internet-based
message boards. Thus, through a combination of approaches,
researchers may be able to compensate for low levels of
institutional subscription, but the time and energy necessary to
obtain articles in this way undoubtedly puts an additional burden
on those researchers who are already constrained in resources.
Interestingly, contacting authors directly no longer appears to
be a common approach to obtain reprints of publications. Our
experience may provide some clues as to why this is the case. The
response rate to reprint requests of only 50–60% and the not
uncommon long delay in response make contacting authors a very
unreliable and time-consuming way to access articles. Moreover,
even though contact information of the corresponding author is
usually available for recently published articles on the journal’s
website, it is frequently missing for older literature, creating a
‘‘catch 22’’ situation in which only those individuals with access to
the paper online or in hard copy know the contact information of
the corresponding author. Even when this information is available,
it can be outdated. The decay of emails [14] contributed to the
low-response rate we observed – out of 65 emails we checked, 8
could not be located and another 8 were outdated and bounced
back. One potential solution to the problem of email decay is
adoption of a system of unique IDs for researchers that allow
tracking authors as they move from one institution to another or
even completely leave the field.
The ‘‘green road to open access’’ relies on researchers archiving
their final peer-reviewed drafts on personal websites or in
institutional repositories [15]. Our study showed that only a very
small number of researchers (2.5%) used this option, even though
many journals allow this practice. Increasing the number of self-
archived articles will depend on stronger institutional mandates
requiring researchers to make their findings available, and on
informing scientists of this opportunity as some may be unaware
that it is allowed under contracts with many journals. The
RoMEO database is a useful source of information that allows
researchers to check quickly journal’s policies regarding self-
archiving [16]. The open-source EPrints software (www.eprints.
org) allows anyone to setup a ‘‘green access’’ repository of scientific
papers to which authors can contribute preprints and postprints.
The software also simplifies the process of obtaining reprints from
authors by providing an automated request to which the author
can reply with a single click of a mouse. If widely adopted, this
approach would save time and effort for both researchers in need
of the manuscript, and authors, who would be more likely to
respond to such requests.
The focus of this study was on HIV vaccine research, an area of
biomedical research that is especially relevant to researchers
working on global health issues and to researchers who live and
work in those areas of the world preferentially affected by the
AIDS epidemic. It would be of interest to investigate whether
other areas of research that preferentially affect the developing
world follow a similar pattern. While this study is small and
preliminary, it reveals the complexity of the issue. We observed
large differences in the level of subscription-provided access
amongst institutions globally, but it is not immediately clear how
these differences in access affect the conduct and pace of research
at these institutions. Access to the latest results is essential for
progress in science. Clearly, if scientists around the world are to
contribute fully to the global efforts to control and eradicate
diseases that preferentially affect the developing world, they must
do so on as level a playing field as possible.
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Table 1. Sample quotes from researchers, who were asked how they access papers, which require subscription, but are not
available through subscription at their institution.
Ways to access Quotes
Web forums ‘‘When we need a paper, which we don’t have access to,
we ask our colleagues on web forum […] and they usually help’’
Collaborations or
joint affiliations
‘‘we do use a login for a European university that one
of our students was registered at’’
‘‘I am fortunate that I still have my [US university] access’’
(from someone moving from US to an institute in Africa)
‘‘[We have] passwords for [Australian University] and [European
University] because two of our doctors are from those institutions’’
‘‘scientists in our labs … have access through their collaboration
to the vast university library collections’’
Colleagues at
other institutes
‘‘if I can’t get a paper, I email friends overseas to download it for me’’
‘‘I use my friends. I am lucky I have people who have sort of taken the
habit in the last 6 months to forward me the things they download.’’
Personal subscriptions ‘‘I personally subscribe to three journals, which I then
donate to the library of the institute’’
doi:10.1371/journal.pone.0027868.t001
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